in vivo News and Research

RSS

Patients with eye diseases can benefit from ArtCornea

Blindness is often caused by corneal diseases. The established treatment is a corneal transplant, but in many cases this is not possible and donor corneas are often hard to come by. In the future, an artificial cornea could make up for this deficiency and save the vision of those affected.

5 Oct 2012

New mouse model could foster ALS, Paget's and dementia breakthroughs

Efforts to treat disorders like Lou Gehrig's disease, Paget's disease, inclusion body myopathy and dementia will receive a considerable boost from a new research model created by UC Irvine scientists.

3 Oct 2012

New positively-charged nanoparticles can be useful MRI agents to monitor transplanted islet cells

In a study to investigate the detection by MRI of six kinds of positively-charged magnetic iron oxide nanoparticles designed to help monitor transplanted islet cells, a team of Japanese researchers found that the charged nanoparticles they developed transduced into cells and could be visualized by MRI while three kinds of commercially available nanoparticles used for controls could not.

3 Oct 2012

Inhibiting TRPV4 protects against diet-induced obesity, inflammation and insulin resistance

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.

28 Sep 2012

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."

27 Sep 2012

Advanced optics system noninvasively maps out network of tiny blood vessels beneath the skin

The trained eye of a dermatologist can identify many types of skin lesions, but human sight only goes so far. Now an international team of researchers has developed an advanced optics system to noninvasively map out the network of tiny blood vessels beneath the outer layer of patients' skin, potentially revealing telltale signs of disease.

24 Sep 2012

Bruker to purchase preclinical imaging product portfolio and related assets from Carestream

Carestream Health and Bruker have entered into an agreement for Bruker to purchase the preclinical in-vivo imaging equipment product portfolio and related assets from Carestream's Molecular Imaging business. Financial terms of the agreement are not being disclosed.

24 Sep 2012

PCA inhibits multiple pathways involved in development of diabetic nephropathy

Diabetic nephropathy is one of the most serious complications related to diabetes, often leading to end-stage kidney disease. Purple corn grown in Peru and Chile is a relative of blue corn, which is readily available in the U.S.

20 Sep 2012

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.

17 Sep 2012

Progenra’s P5091 inhibits growth of bortezomib resistant multiple myeloma tumor cells

Researchers at the Dana-Farber Cancer Institute and Progenra, Inc. announce the publication of a research article entitled "A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance."

17 Sep 2012

Solubilized curcumin shrinks lung tumors in mice

Belgian researchers report that orally administered curcumin can reduce the size of lung cancer tumors in mice.

13 Sep 2012

Researchers identify novel genes that make some children cope with malaria

Researchers from Sainte-Justine University Hospital Center and University of Montreal have identified several novel genes that make some children more efficient than others in the way their immune system responds to malaria infection.

12 Sep 2012

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

GE Healthcare today announced pooled results from phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent, [18F]flutemetamol, which showed a strong concordance between [18F]flutemetamol images and Alzheimer's disease-associated beta amyloid brain pathology.

11 Sep 2012

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital. This technology is complimentary to the early Beta cell destruction diagnostic that Islet Sciences licensed last month.

10 Sep 2012

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.

7 Sep 2012

Researchers turn skin cells into embryonic Sertoli-like cells

Using a stepwise trans-differentiation process, Whitehead Institute researchers have turned skin cells into embryonic Sertoli-like cells.

7 Sep 2012

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, today announced top line results from a clinical study showing that the novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in two Phase 1b studies in patients with chronic obstructive pulmonary disease (COPD).

5 Sep 2012

in vivo News and Research

Patients with eye diseases can benefit from ArtCornea

New mouse model could foster ALS, Paget's and dementia breakthroughs

New positively-charged nanoparticles can be useful MRI agents to monitor transplanted islet cells

Inhibiting TRPV4 protects against diet-induced obesity, inflammation and insulin resistance

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Advanced optics system noninvasively maps out network of tiny blood vessels beneath the skin

Bruker to purchase preclinical imaging product portfolio and related assets from Carestream

PCA inhibits multiple pathways involved in development of diabetic nephropathy

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

Progenra’s P5091 inhibits growth of bortezomib resistant multiple myeloma tumor cells

Solubilized curcumin shrinks lung tumors in mice

Researchers identify novel genes that make some children cope with malaria

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Researchers turn skin cells into embryonic Sertoli-like cells

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

IVIVC and Biowaivers in Drug Development 2012 seminar to take place in India

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Johns Hopkins team creates synthetic protein that can help locate tumors

eBook: Using iPSCs models for human disease research and drug discovery eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News